← All trials
NCT03441100
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 2, 2019
- Primary completion
- Jun 17, 2022
- Completion date
- Mar 17, 2023
- First posted
- Feb 22, 2018
- Last posted
- Apr 28, 2023
- Enrollment
- 16
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- immatics Biotechnologies GmbHLead sponsor
- immatics Biotechnologies GmbHStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.